Skip to main content
Skip to header right navigation
Skip to site footer

Endogenex

Bringing New Energy to the Treatment of Type 2 Diabetes

T2D
ReCET
Patients
Clinical Providers
About Us
- News
- Contact
ReCET Study

Jennifer Strumbel

Endogenex

Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025

* Caution: Exclusively a clinical investigational device. Limited by federal (or United States or similar) law to investigational use. Not for sale in any geography.

Please refer to your physician for additional information on the ReCET Procedure, ReCET System, and related risks.

Endogenex, Inc.
13755 1st Avenue North #100
Plymouth, MN 55441
+1 763-251-6820
info@endogenex.com

Endogenex^TM and ReCET^TM are registered trademarks of Endogenex, Inc. in the United States and other countries. Copyright © 2025 Endogenex, Inc. All rights reserved.

LinkedIn
X
Vimeo